Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301

NCT06112314 is registered in ClinicalTrials.gov with Immunocore Ltd as lead sponsor.

NCT NCT06112314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06112314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301
Lead sponsor
Immunocore Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
June 5, 2024
Completion date
October 16, 2027
Enrollment
680 (estimated)
Sites
211

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma